As autoantibodies continue to gain attention as potential biomarkers in the field of immunology, CDI Labs' HuProt™ Proteome Microarray is revolutionizing disease research by unveiling new biomarkers and therapeutic targets that have the potential to transform patient care.

The HuProt Microarray has been used to identify autoantibody signatures that have the potential to predict both disease recurrence and immune-related adverse events in melanoma patients treated with checkpoint inhibitor adjuvant immunotherapy¹. HuProt was also used to support findings that indicate that immunotherapies that boost both coordinated B and T cell responses against human ovarian cancer - an immunogenic disease that is currently resistant to checkpoint inhibitors - are likely to show increased therapeutic benefit².

HuProt features:

1 Paul Johannet, Iman Osman. et al. Baseline Serum Autoantibody Signatures Predict Recurrence and Toxicity in Melanoma Patients Receiving Adjuvant Immune Checkpoint Blockade. Clin Cancer Res (2022)

2 Biswas, S., Mandal, G., Payne, K.K. et al. IgA transcytosis and antigen recognition govern ovarian cancer immunity. Nature 591, 464–470 (2021).

Tyler Hulett, PhD

CSO, CDI Labs

Tuesday, June 18

6:00 - 7:30 pm (Salon 9, Lower B2 Level)

Poster: Tu138

High-throughput Serology of Identical Twin Ageing Demonstrates Stability and Genetic Independence of Antibody Memory

Recent advances in high-throughput synthetic biology tools enable massively multiplexed serologic profiling of antigen-specific antibody repertoires by proteome microarray and phage-display immunoprecipitation sequencing (PhIP-Seq). However, little remains known about the impact of individual genetics on these global profiles or repertoire stability across time.

FOR RESEARCH USE ONLY. Not for use in diagnostic procedures.

© 2024 CDI Labs. All rights reserved

CDI Labs, HuProt, VirD and the CDI Labs logo are trademarks of CDI Labs.

This is a marketing email from CDI Labs | Mayaguez, Puerto Rico | Baltimore, MD.

CDI Labs privacy policy